Clinical trial · Observational
Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma
Identification and Characterization of Circulating Tumor Cells Before and After Treatment in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this prospective observational study is to evaluate the presence of circulating tumoral cells in patients over 18 with a stage I-III resectable Merkel cell carcinoma after the initial therapeutic sequence of surgery and radiotherapy. The main question it aims to answer is : Can any residual disease be found in the form of circulating tumoral cells in blood samples of patients treated with surgery and radiotherapy for a resectable, stage I to III Merkel cell carcinoma ? When possible, the circulating tumoral cells count will be compared to the one realized in a blood sample of the same patient before surgery and radiotherapy. Participants will : * Have a blood sample taken before surgery (if the patient is addressed to our center early enough), * Have a blood sample taken immediately after surgery and radiotherapy (for all). * Two additional blood samples will be taken during the 6-months and 12-months visit to set up a biobank.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Merkel Cell Carcinoma | Merkel Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood Test | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma
- description
- Entire cohort
- interventionNames
- Other: Blood Test
Primary outcomes (1)
- measure
- Circulating tumoral cells detection rate
- timeFrame
- 6 weeks or less after the therapeutic sequence of surgery and radiotherapy
- description
- Rate of patients with the presence of at least one CTC detected in the peripheral blood directly after the therapeutic sequence of surgery and radiotherapy, in absolute value
Secondary outcomes (1)
- measure
- Change in the number of pre- and post-therapeutic circulating tumoral cells
- timeFrame
- 6 weeks or less after the therapeutic sequence of surgery and radiotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients at least 18 years old * Patients managed for stage I to III Merkel cell carcinoma, * For whom complete remission by complete surgical resection is planned (group B) or has been achieved recently, within 6 weeks prior to the inclusion visit (group A). Exclusion Criteria: * Pregnant or breast-feeding women * Failure to obtain written informed consent after a reflection period * Participant in another research study with an ongoing exclusion period * Not affiliated to a social security scheme * Persons under court protection * Patients unable to give consent, protected adults, vulnerable persons * Stage IV disease or stage I to III disease for which complete remission is not envisaged
References
Publications (0)
Data not yet available